EXICURE INC (XCUR) Fundamental Analysis & Valuation

NASDAQ:XCUR • US30205M3097

3.55 USD
-0.07 (-1.93%)
At close: Mar 3, 2026
3.7 USD
+0.15 (+4.23%)
After Hours: 3/3/2026, 9:46:21 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This XCUR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

XCUR gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. While XCUR seems to be doing ok healthwise, there are quite some concerns on its profitability. XCUR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. XCUR Profitability Analysis

1.1 Basic Checks

  • XCUR had negative earnings in the past year.
  • In the past year XCUR has reported a negative cash flow from operations.
  • XCUR had negative earnings in each of the past 5 years.
  • In the past 5 years XCUR always reported negative operating cash flow.
XCUR Yearly Net Income VS EBIT VS OCF VS FCFXCUR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • XCUR has a Return On Assets (-60.45%) which is in line with its industry peers.
  • XCUR has a Return On Equity of -133.23%. This is in the lower half of the industry: XCUR underperforms 61.92% of its industry peers.
Industry RankSector Rank
ROA -60.45%
ROE -133.23%
ROIC N/A
ROA(3y)-73.86%
ROA(5y)-68.98%
ROE(3y)-239.53%
ROE(5y)-266.21%
ROIC(3y)N/A
ROIC(5y)N/A
XCUR Yearly ROA, ROE, ROICXCUR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • XCUR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XCUR Yearly Profit, Operating, Gross MarginsXCUR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. XCUR Health Analysis

2.1 Basic Checks

  • XCUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • XCUR has more shares outstanding than it did 1 year ago.
  • XCUR has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for XCUR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
XCUR Yearly Shares OutstandingXCUR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
XCUR Yearly Total Debt VS Total AssetsXCUR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • XCUR has an Altman-Z score of -18.64. This is a bad value and indicates that XCUR is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -18.64, XCUR is doing worse than 82.12% of the companies in the same industry.
  • There is no outstanding debt for XCUR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.64
ROIC/WACCN/A
WACC8.69%
XCUR Yearly LT Debt VS Equity VS FCFXCUR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

  • XCUR has a Current Ratio of 1.96. This is a normal value and indicates that XCUR is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.96, XCUR is doing worse than 76.92% of the companies in the same industry.
  • A Quick Ratio of 1.96 indicates that XCUR should not have too much problems paying its short term obligations.
  • XCUR has a worse Quick ratio (1.96) than 75.38% of its industry peers.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.96
XCUR Yearly Current Assets VS Current LiabilitesXCUR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. XCUR Growth Analysis

3.1 Past

  • The earnings per share for XCUR have decreased strongly by -35.80% in the last year.
  • XCUR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
  • XCUR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -17.40% yearly.
EPS 1Y (TTM)-35.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.89%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-17.4%
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XCUR Yearly Revenue VS EstimatesXCUR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2024 0 5M 10M 15M 20M 25M
XCUR Yearly EPS VS EstimatesXCUR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. XCUR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for XCUR. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XCUR Price Earnings VS Forward Price EarningsXCUR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XCUR Per share dataXCUR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XCUR Dividend Analysis

5.1 Amount

  • No dividends for XCUR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XCUR Fundamentals: All Metrics, Ratios and Statistics

EXICURE INC

NASDAQ:XCUR (3/3/2026, 9:46:21 PM)

After market: 3.7 +0.15 (+4.23%)

3.55

-0.07 (-1.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-16
Inst Owners6.15%
Inst Owner Change-60.74%
Ins Owners0%
Ins Owner Change-9.71%
Market Cap22.61M
Revenue(TTM)N/A
Net Income(TTM)-9.23M
Analysts43.33
Price TargetN/A
Short Float %1.53%
Short Ratio1.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.26
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.07
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0
BVpS1.09
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -60.45%
ROE -133.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.86%
ROA(5y)-68.98%
ROE(3y)-239.53%
ROE(5y)-266.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.96
Quick Ratio 1.96
Altman-Z -18.64
F-Score3
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.89%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-17.4%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-85.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.94%
OCF growth 3YN/A
OCF growth 5YN/A

EXICURE INC / XCUR FAQ

Can you provide the ChartMill fundamental rating for EXICURE INC?

ChartMill assigns a fundamental rating of 1 / 10 to XCUR.


What is the valuation status of EXICURE INC (XCUR) stock?

ChartMill assigns a valuation rating of 0 / 10 to EXICURE INC (XCUR). This can be considered as Overvalued.


How profitable is EXICURE INC (XCUR) stock?

EXICURE INC (XCUR) has a profitability rating of 0 / 10.


How financially healthy is EXICURE INC?

The financial health rating of EXICURE INC (XCUR) is 5 / 10.